| Autor: |
Muthusamy B; Department of Hematology and Medical Oncology, Cleveland Clinic-Taussig Cancer Institute, Cleveland, OH, USA., Pennell NA; Department of Hematology and Medical Oncology, Cleveland Clinic-Taussig Cancer Institute, Cleveland, OH, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Translational lung cancer research [Transl Lung Cancer Res] 2023 Jul 31; Vol. 12 (7), pp. 1649-1651. Date of Electronic Publication: 2023 May 22. |
| DOI: |
10.21037/tlcr-23-237 |
| Abstrakt: |
Competing Interests: Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-237/coif). NAP received consulting fees from Merck, Pfizer, Mirati, Eli Lilly, Genentech, Sanofi Genzyme, Novartis, Takeda, Bayer, Summitt Therapeutics, and Anheart for participating in the Advisory Board. The other author has no conflicts of interest to declare. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
